Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Lung Neoplasms 9Glioblastoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Brenner Tumor 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Oligodendroglioma 3Carcinoma 3Astrocytoma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mouth Neoplasms 2Medulloblastoma 2

Interventions

Specimen Handling 6Nivolumab 6Magnetic Resonance Spectroscopy 6Platinum 4Cisplatin 41,2-diaminocyclohexaneplatinum II citrate 4Gemcitabine 3Carboplatin 3Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2relatlimab 1fluciclovine F-18 1cemiplimab 1cabozantinib 1atezolizumab 1X-Rays 1Transurethral Resection of Bladder 1Radiotherapy 1Radiation 1Phantoms, Imaging 1Docetaxel 1Cetuximab 1Bevacizumab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Nasopharyngeal Carcinoma × Immunoglobulin G × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡